Zen LifeSciences Inc. is making a major P1.2-billion investment in local pharmaceutical manufacturing, announcing plans to build a state-of-the-art production facility at the Luisita Industrial Park–Special Economic Zone in Tarlac.
The Filipino-owned company will produce a wide range of medical, wellness, and general healthcare products aimed at both domestic and export markets.
Zen LifeSciences recently secured registration with the Philippine Economic Zone Authority as a new export enterprise after signing its PEZA registration agreement on January 19.
The P1.2-billion project is scheduled to begin commercial operations in January 2027 and is expected to create jobs for more than 90 Filipinos.
PEZA Director-General Tereso Panga, who signed the registration agreement with Zen LifeSciences President Maximo Ponce Balajadia, said the investment reinforces the Marcos administration’s push to strengthen the country’s pharmaceutical manufacturing base.
“The registration of Zen LifeSciences Inc. is aligned with President Ferdinand R. Marcos Jr.’s thrust to enhance domestic pharmaceutical production and reduce reliance on imported medicines,” Panga said.
He added that locating inside a PEZA ecozone helps ensure a steady supply of high-quality, locally manufactured health products while supporting exports.
The project is also expected to generate sustainable employment and spur economic activity in Tarlac and nearby communities.
Industry observers say the investment underscores growing confidence in the Philippines as a viable hub for pharmaceutical manufacturing amid regional supply chain realignments.
For Zen LifeSciences, the Tarlac facility positions the company to scale up production, meet global standards, and compete in increasingly demanding health markets.
Construction activities are expected to ramp up following preparatory works, with commercial rollout marking a milestone for homegrown pharma investments.
More investments are anticipated as policy support and demand converge over the next several years.
